The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.
In November 2014, the Pharmacovigilance Centre of Netherlands (Lareb) provided an updated overview of Dutch cases of narcolepsy reported to have a link to Pandemrix.
On 8 January 2014, Canada reported a fatal imported case of influenza A(H5N1) infection. This is the first confirmed human case of H5N1 in North America.
This is the first published study where an attempt has been made to understand the possible biological mechanisms behind development of narcolepsy following vaccination with Pandemrix™.
This observational cohort study utilizing electronic health care records covering 5.8 million Swedes confirmed an increased risk of narcolepsy after vaccination with Pandemrix in children and adolescents (<
This is the sixth EU Member State reporting an association between the development of narcolepsy and vaccination with the AS03-adjuvanted influenza A H1N1 (2009) pandemic vaccine Pandemrix.
This systematic review and meta-analysis of observational data from an established group of specialists assessed treatment outcomes for all three neuraminidase inhibitors (NAIs); oseltamivir, zanamivir and peramivir given to hospitalised patients with influenza A(H1N1)pdm09 during the 2009 pandemic.
In September 2010 Sweden and Finland noted a number of children had developed narcolepsy seemingly in association with having received the pandemic vaccine used almost exclusively in those countries (Pandemrix)